H9 cell clones susceptible to HIV isolates
OHSU # 0463
Optimal development and evaluation of antiviral drugs and vaccines to HIV depend on cell culture studies using HIV-1 isolates that are representative of patient viruses. Many of the early HIV-1 isolates used were laboratory adapted strains which grew well in leukemic T cell lines such as H9. However, it was later realized that these laboratory adapted strains were different from primary patient isolates, and HIV-1 isolates from patients grow poorly in leukemic T cell lines.
In order to overcome this hurdle, several derivatives of the H9 cell line were generated that express 10- to 12-fold greater amounts of CD4. These derivative cells are able to support the enhanced replication of most primary patient isolate strains of HIV-1 that have been tested. Moreover, the viruses produced by infections in these H9-derivative cells retain the typical properties of primary patient isolates. These cells can be used for HIV research studies and drug screening.
With more than 6500 new infections daily, HIV has become one of the most catastrophic pandemics to confront mankind. Despite the availability of >20 approved antiretroviral drugs, there is continued interest in developing new agents for the treatment of HIV/AIDS. This is due to increasing resistance to existing drugs, need for better tolerated, more convenient and less expensive treatments, and the fact that an effective vaccine is still many years away. Research and drug development efforts on HIV continue to increase. During the past decade, the NIH has nearly doubled its annual HIV/AIDS research budget. In 2007, the NIHâ€™s research budget for HIV/AIDS research was around $3 billion. Also during the past decade the funding for HIV/AIDS research and treatment in low- and middle-income countries has exploded, jumping more than 20-fold to $10 billion in 2007.
Dr. David Kabat is a Professor in the Biochemistry and Molecular Biology Department at Oregon Health & Science University. He received his B.S. from Brown University and Ph.D. from the California Institute of Technology. Prior to coming to OHSU, Dr. Kabat held positions at MIT and the University of Oregon Medical School, now OHSU.
AIDS Research and Human Retroviruses, Vol. 16(9), 2000: 871-882
The H9-derivative cell clones are available for non-exclusive licensing.
- David Kabat, SM.Biochemistry & Molecular Biology
- OHSU # 0463-A — H9 cell clone H9.35 susceptible to HIV isolates
- OHSU # 0463-B — H9 cell clone H9.38 susceptible to HIV isolates
- OHSU # 0463-C — H9 cell clone H9.42 susceptible to HIV isolates
For more information, contact:
Technology Development Manager